Upon
searching for more sources on EBSCOhost, I found two more very intriguing
journal articles discussing new ways in developing embryonic stem cells and how
this may bring an end to the ethical issues, and the problems that may be
presented when going from animal to clinical application.
The article “Will
Cell Reprogramming Resolve the Embryonic Stem Cell Controversy?”, written by
John Rasko and Carl Power, addressed the ongoing developments of cell
reprogramming. This is where “adult” stem cells are reprogrammed to enter an
embryonic stem cell state. They are deemed “pluripotent stem cells” and many
scientists feel these will help break away from the ethical controversy
regarding embryonic stem cells. Cell reprogramming, to some, seems to be the
new way to use embryonic stem cells clinically and the future of regenerative
medicine. However the article also emphasizes that pluripotent stem cells may
also cause more ethical problems and complicate the stem cell controversy even
further.
Given that
there is really no conclusion to this ongoing controversy of embryonic stem
cell use, the President’s Council on Bioethics stated that the best “ethical
alternative” at this point, is cell reprogramming. It has been very successful
in the lab, where researchers turned human skin cells into red blood cells. Not
to mention, induced pluripotent stem cells can be collected from any individual
and differentiate into any cell type just like embryonic stem cells. Yet problems
can still occur depending on the age of the donor cells, as they are less
efficient the older they are. I don’t sense any bias in this source but I do
question if this alternative, could bring an end to the ethical controversy
attached to this topic, given there are still minor problems associated with
it.
http://www.stemcellresearchfoundation.org/WhatsNew/Pluripotent.htm
I also find myself
wondering; could induced pluripotent stem cells be just as effective, if not
better, then embryonic stem cells? What concerns, if any, are attached to iPS
cells? Will the government decide to fund this new form of regenerative
medicine? At this point, it is hard to say but if iPS cells prove to
differentiate just as well as embryonic stem cells, will this
ultimately become the new direction of regenerative medicine?
I also
explored the problems that may develop when taking embryonic stem cells from
the lab setting, with animals, to the clinical setting. “New Perspectives in
Stem Cell Research: Beyond Embryonic Stem Cells,” written by L. Keller,
discussed the current state of stem cell technology and applying embryonic stem
cells to disease treatment and cell replacement therapy. The article also
addresses the problems faced when applying them in a clinical setting.
Embryonic stem cells were recently cleared to be used, clinically, in a trial to
treat spinal cord injuries; however it is now on hold due to some minor issues
that arose in the final tests in the lab.
Although “adult”
stem cells have continually been used in the clinical setting, the real
question is how embryonic stem cells will transition to the clinical setting. Yes
human embryonic stem cells have been tested in the lab, but I think the lack of
funding by the government may ultimately determine just how effective they are
in the clinical setting.
As noted in
the article, there is also major concern with the transition of embryonic stem
cells to a clinical setting, in that although they have unlimited reproduction,
this may end up causing tumors. Another problem arises in that cells from an
embryo, injected into a sick patient, may be rejected given the cells are no
the genetically the same as the patient. Not to mention, human embryos are not
an unlimited “resource,” so this may slow down large-scale treatment. However until
they are allowed to be used clinically, and not just “here-and-there” in a lab,
it is difficult to come to a conclusion of just how successful embryonic stem
cells may or may not be.
The beginning
of organ transplants had similar concerns attached, those being if it could be
done in the clinical setting as well and the fear of patient rejection. Many were
reluctant to attempt or even allow it to be done. Though once proven to work,
and the “kinks” sort of worked out, organ transplants became widely accepted. I
realize there are not ethical issues related to this, as there are with embryonic
stem cell use, but I feel both can be looked at in the same light. If embryonic
stem cells work clinically, will this new disease treatment be accepted
medically?
If proven to
work in the clinical setting, will the government fund more research and
trials? How will success rate affect individual concerns regarding this topic? Will
more ethical issues arise if proven to work? Again coming to conclusions about
success and individual morals is not something that can really be determined. However
I’m looking forward to seeing what new disease treatments regenerative medicine
may lead to in the future, once some laboratory and clinical hurdles are cleared.
Works Cited
L. Kenner, et al. "New Perspectives In Stem
Cell Research: Beyond Embryonic Stem Cells." Cell Proliferation
44.(2011): 9-14. Academic Search Premier. Web. 14 July 2012.
Power, Carl, and John E. J. Rasko.
"Will Cell Reprogramming Resolve The Embryonic Stem Cell Controversy? A
Narrative Review." Annals Of Internal Medicine 155.2 (2011):
114-W43. Academic Search Premier. Web. 14 July 2012.